Physio-somatic symptoms in schizophrenia: association with depression, anxiety, neurocognitive deficits and the tryptophan catabolite pathway

Physio-somatic symptoms in schizophrenia: association with depression, anxiety, neurocognitive deficits and the tryptophan catabolite pathway

Author Kanchanatawan, Buranee Google Scholar
Sirivichayakul, Sunee Google Scholar
Thika, Supaksorn Google Scholar
Ruxrungtham, Kiat Google Scholar
Carvalho, Andre F. Google Scholar
Geffard, Michel Google Scholar
Anderson, George Google Scholar
Noto, Cristiano Autor UNIFESP Google Scholar
Ivanova, Rada Google Scholar
Maes, Michael Google Scholar
Abstract To investigate the frequency of physio-somatic symptoms (PS) symptoms in schizophrenia and their relation to positive, negative and affective symptoms

neurocognitive deficits and impairments in the tryptophan catabolite (TRYCAT) pathway. Eighty four patients with schizophrenia and 40 healthy controls were assessed using the 12 item Fibromyalgia and Chronic Fatigue Syndrome Rating scale (FF) and scales for negative and positive symptoms, depression and anxiety. Cognitive functioning was tested using the Cambridge Neuropsychological Test Automated Battery (CANTAB). Other assessments included: immunoglobulin (Ig)A and IgM responses to tryptophan catabolites (TRYCATs), namely quinolinic (QA), 3-OH-kynurenine (3HK), picolinic (PA), xanthurenic (XA) and kynurenic acid (KA) and anthranilic acid (AA). More than 50% of the patients studied had elevated levels of physio-somatic (PS) symptoms, significantly co-occurring with depression and anxiety, but not with negative or positive symptoms. PS symptoms were significantly associated with IgA/IgM responses to TRYCATs, including increased IgA responses to 3 HK, PA and XA, and lowered IgA to QA and AA. Fatigue, muscle pain and tension, autonomic and cognitive symptoms and a flu-like malaise were strongly associated with cognitive impairments in spatial planning and working memory, paired associative learning, visual sustained attention and attention set shifting. PS symptoms in schizophrenia aggregate with depression and anxiety symptoms and may be driven by TRYCAT patterning of IgA/IgM-responses, with IgA indicating mucosal-mediated changes and IgM indicating regulatory functions. As such, the patterning of IgA/IgM responses to TRYCATs may indicate differential TRYCATs regulation of neuronal and glia activity that act to regulate PS signalling in schizophrenia.
Keywords Schizophrenia
Depression
Chronic fatigue
Neurocognitive impairments
immune
Cytokines
Leaky gut
Inflammation
Language English
Sponsor Asahi Glass Foundation
Chulalongkorn University Centenary Academic Development Project
IDRPHT
Gemac, France
Date 2017
Published in Metabolic Brain Disease. New York, v. 32, n. 4, p. 1003-1016, 2017.
ISSN 0885-7490 (Sherpa/Romeo, impact factor)
Publisher Springer/Plenum Publishers
Extent 1003-1016
Origin http://dx.doi.org/10.1007/s11011-017-9982-7
Access rights Closed access
Type Article
Web of Science ID WOS:000405327200009
URI http://repositorio.unifesp.br/handle/11600/51506

Show full item record




File

File Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Search


Browse

Statistics

My Account